<DOC>
	<DOCNO>NCT02285842</DOCNO>
	<brief_summary>MicroPort Orthopedics ( MPO ) conduct PMCF study evaluate safety efficacy THA resurface component market EU . These type study require regulatory authority THA resurface device medium long-term clinical evidence available time gain approval market EU . This study design accordance MEDDEV 2.12/2 rev 2 .</brief_summary>
	<brief_title>Post Market Clinical Follow-Up Study Protocol CONSERVEÂ® Press-Fit Femoral Components</brief_title>
	<detailed_description />
	<mesh_term>Joint Diseases</mesh_term>
	<criteria>Has undergone primary hip resurface follow : Noninflammatory degenerative joint disease osteoarthritis , avascular necrosis , ankylosis , protrusio acetabuli , painful hip dysplasia ; Inflammatory degenerative joint disease rheumatoid arthritis ; Correction functional deformity Subject implant specified combination component Subject willing able complete require study visit assessment Subjects skeletally immature ( less 21 year age ) time primary resurface surgery Subjects currently enrol another clinical study Subjects unwilling sign Informed Consent document Subjects substance abuse issue Subjects incarcerate pending incarceration</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>avascular necrosis</keyword>
	<keyword>ankylosis</keyword>
	<keyword>protrusio acetabuli</keyword>
	<keyword>painful hip dysplasia</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>correction functional deformity</keyword>
	<keyword>revision procedure</keyword>
</DOC>